Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nyenrode. Already before starting Aglaia, he had been involved in the founding, restructuring and funding of multiple technology-driven companies. Within Aglaia he covers legal and finance. He serves on the board of a number of life sciences companies.
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018
Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline